focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,166.00
Bid: 12,132.00
Ask: 12,136.00
Change: -6.00 (-0.05%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Global stocks rise ahead of Fed meeting

Tue, 16th Mar 2021 19:47

* Graphic: Global asset performance http://tmsnrt.rs/2yaDPgn

* Graphic: World FX rates http://tmsnrt.rs/2egbfVh

By Herbert Lash

NEW YORK, March 16 (Reuters) - Wall Street's S&P 500 index
scaled a new high on Tuesday and a gauge of global equities
neared an all-time peak as investors bet the Federal Reserve and
other central banks meeting this week will retain policies
supporting a post-pandemic recovery.

U.S. stocks retreated late in the session, with the Nasdaq
shedding more than a 1% gain, as yields on longer-maturity U.S.
Treasury bonds ticked up, nipping investor enthusiasm for
tech-stocks that are high growth but wary of rising inflation.

The U.S. dollar edged up against the euro and commodity
currencies such as the Australian and New Zealand dollars as the
two-day Fed meeting kept trading from being volatile.
.

But oil prices fell for a third day after Germany, France
and other European countries suspended use of AstraZeneca's
vaccine, threatening economic growth and fuel demand, and
tarnishing roll-outs as a pillar for a global recovery.

Speculation about what the Fed will say on Wednesday at the
end of its two-day meeting kept markets mostly range-bound.

"The hope out there, for at least some investors, is they do
an Operation Twist - buying long-term bonds and selling short
bonds to help the economy," said Tim Ghriskey, chief investment
strategist at Inverness Counsel in New York.

The Nasdaq rose to a two-week high on a rebound in tech
stocks at the heart of February's sell-off. MSCI's benchmark for
global equity markets, which is heavily weighted to the big U.S.
technology firms, advanced 0.3% to 679.01.

After the coronavirus pandemic, demand will increase further
for technology stocks, according to Johan Grahn, head of ETF
strategy at AllianzIM in Minneapolis.

"As long as technology is solving real problems for people,
there will continue to be a market for these types of
companies," Grahn said. "There will be more demand for
technology solutions across the board."

European stocks rose after an upbeat forecast from German
carmaker Volkswagen prompted a rally in the automobiles sector.
The broad FTSEurofirst 300 index rose 0.8%, closing in
on its record peak of February 2020, while the regional autos
sector jumped 2.1% to its highest level since June 2018.

On Wall Street, the Dow Jones Industrial Average fell
0.19%, the S&P 500 gained 0.07% and the Nasdaq Composite
added 0.36%.

Euro zone government bonds held ground as caution set in
before the Fed meeting.

Longer-term U.S. Treasury yields initially slipped as the
market looked ahead.

The 10-year U.S. Treasury note rose 0.4 basis
points to yield 1.6109%. Yields on the benchmark last week hit
1.642% on expectations of rising inflation.

The Fed is targeting maximum employment and higher inflation
expectations, and will do whatever it can to get higher
inflation, said Steven Ricchiuto, U.S. chief economist at Mizuho
Securities USA LLC in New York.

"This is what is motivating the sell-off in the 10-year
note, and there are a lot of people who are just basically
coming around to recognizing that," Ricchiuto said.

Fed policymakers are expected to forecast the U.S. economy
will grow in 2021 by the fastest rate in decades as it recovers
from a coronavirus-stricken 2020.

The Bank of England also meets this week, on Thursday, and
the Bank of Japan wraps up a two-day meeting on Friday.

The outlook for post-pandemic recoveries continued to
diverge between the United States and Europe.

President Joe Biden's order to make vaccinations available
to all adults by May 1 contrasted with stuttering roll-outs in
Germany, France and elsewhere, where use of the AstraZeneca
vaccine has been suspended amid concern over possible
serious side-effects.

In currencies, the dollar held small gains from overnight,
with caution evident ahead of the central bank meetings.

The dollar index rose 0.001%, with the euro
down 0.17% to $1.1908.

The Japanese yen strengthened 0.14% versus the
greenback at 108.97 per dollar.

Gold edged lower, pressured by a stronger dollar. U.S. gold
futures settled up 0.1% at $1,730.90.

Europe's medicines watchdog said the benefits of the
AstraZeneca vaccine outweigh its risks, but investors worry the
slow pace of vaccinations in the European Union could dampen
both the recovery and fuel demand.

Brent crude futures settled down 49 cents at $68.39
a barrel and U.S. crude futures fell 59 cents to settle
at $64.80 a barrel.

(Reporting by Herbert Lash with additional reporting by Ritvik
Carvalho in London and by Kevin Buckland and Kane Wu in Tokyo
Editing by Mark Potter and Mark Heinrich)

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.